A Phase 1, Open-Label, Fixed-Sequence, Crossover Drug-Drug Interaction Study in Healthy Subjects to Determine the Effects of a Strong Inducer of Cytochrome P450 3A on Exposure to Mifepristone and Its Metabolites
Latest Information Update: 05 Nov 2021
Price :
$35 *
At a glance
- Drugs Mifepristone (Primary) ; Rifampicin
- Indications Breast cancer; Cushing syndrome; Induced abortion; Prostate cancer
- Focus Pharmacokinetics
- Sponsors Corcept Therapeutics
- 02 Nov 2017 Status changed from active, no longer recruiting to completed.
- 28 Aug 2017 New trial record